Mylan awarded $106.7M in suit against Glaxo
CANONSBURG – Mylan Inc. said Thursday it has won a breach of contract lawsuit against GlaxoSmithKline related to Paroxetine Hydrochloride Extended-release tablets.
Following the verdict, delivered after a trial in the U.S. District Court for New Jersey, GSK was ordered to pay Southpointe-based Mylan $106.7 million in damages.
Mylan’s claims were based on 2007 agreements with GSK relating to Mylan’s abbreviated new drug application for the medicine, which is used to treat depression.
Mylan said in a news release pursuant to those agreements, it obtained certain intellectual property rights from GSK. Mylan, the largest generic pharmaceutical company in the United States, then launched its generic version of GSK’s Paxil in May 2008 and, to date, is the only company to have received FDA approval of an ANDA for this product.